UDP Glucuronosyltransferase 2B15 (UGT2B15) Genotyping
Many drugs and endogenous biomolecules are subject to phase II biotransformation, of which the major pathway is glucuronidation catalyzed by the uridine 5-diphosphate-glucuronosyltransferases (UGTs). Following glucuronidation, parent compounds or their metabolites become water soluble and subsequently able to be excreted from the body. Two major UGT families, namely UGT1A and UGT2 (subdivided in UGT2A and UGT2B), are found in the human body. Human UGT1A genes are alternative spliced products from a single gene. In contrast, the UGT2 family has 10 unique genes (UGT2A1, 2A2, 2A3, 2B4, 2B7, 2B10, 2B11, 2B15, 2B17 and 2B28) on chromosome 4q13. The UGT2B15 gene is found on chromosome 4q13.
UGT2B15 is the major glucuronidation enzyme expressed in human liver. Studies have shown its importance for the glucuronidation of androgenic steroids and various drugs, such as E-4-hydroxytamoxifen, 5-hydroxyrofecoxib, eugenol, 8-hydroxyquinoline, phenolphthalein, 4’-hydroxyphenytoin, nandrolone, and bisphenol A. Genotype AA of rs1902023 is associated with decreased oxazepam and sipoglitazar clearance as compared to genotype CC. Patients with the *1/*1 genotype may have a decreased response to sipoglitazar compared to patients with *2/*2 genotype (as measured by HbA1c levels) as well as increased clearance. UGT2B15 conjugates specifically the 17-hydroxyposition of 5α-reduced androgens. Several SNPs within UGT2B15 have been associated with prostate cancer susceptibility and aggressiveness.
- Monitor and manage oxazepam and sipoglitazar therapy
- Risk management for androgen metabolism and prostate cancer
Drug metabolism decreased in:
- rs1902023 (\*2)
Increased risk of prostate cancer:
- rs1902023, rs4148269 and rs3100
253G>T G/G (UGT2B15 *1/*1 genotype) Normal UGT2B15function
Buccal swab and peripheral blood (EDTA) or saliva.
Buccal swabs can be collected by rubbing the inside of the cheeks with a swab (similar to a Q-tip and generally 4 swabs).
The swabs are transported to the laboratory in a liquid medium (see manufacturer guidelines for details) or dry swab.
Stability (Blood)
- Ambient: 3-5 days
- Refrigerated: 5-7 days
- Drug Metab Dispos. 2003; 31: 652–8. [PMID: 12695355]
- Chemosphere. 2008; 74: 33–6. [PMID: 18990428]
- Drug Metab Dispos. 1994; 22: 799–805. [PMID: 7835232]
- Biochem Pharmacol. 2002; 63: 1817–30. [PMID: 12034366]
- Drug Metab Dispos. 2003; 31: 1117–24. [PMID: 12920167]
- BMC Cancer. 2013 Nov 22;13:556. [PMID: 24267955]
- Breast Cancer Research and Treatment. June 2005; 91(3): 249-258. [PMID: 15952058]